
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen has demonstrated impressive sales growth, with a 40% increase in 3Q25 compared to 3Q24, driven by strong performances across multiple therapeutic products, including significant double-digit growth in 16 of its offerings. The recent upward revision of FY25 revenue guidance to a range of $35.8-$36.6 billion from $35.0-$36.0 billion underscores the company’s robust performance and confidence in its established franchises. Furthermore, the anticipated ramp-up in Uplizna sales, with projected worldwide sales expected to reach $1.4 billion by 2027, highlights the company's strategic focus on expanding its therapeutic portfolio to capitalize on market opportunities.
Bears say
Amgen is projected to experience only modest revenue growth of approximately 1% in 2026, largely attributed to significant sales declines expected for key drugs Prolia and Xgeva, with reductions of about 28% and 39%, respectively. Additionally, while the company has a promising pipeline with emerging therapies like MariTide and olpasiran, concerns remain regarding their market viability and limited visibility into their ability to counteract the erosion of its established business. The impending loss of exclusivity for several key product franchises creates structural headwinds that may hinder Amgen's long-term growth prospects, despite the company maintaining steady near-term cash flows.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares